Cardiovascular Risk

Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D

Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias

With insights from the PEGASUS-TIMI 54 study, it was assessed whether patients with higher lipoprotein A treated with ticagrelor, a P2Y12 inhibitor, have a greater reduction in cardiovascular risk. In this touchCARDIO interview, we speak with Dr Siddharth Patel (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the role of lipoprotein […]

With effective treatment currently limited to smoking cessation, REDUCE-IT aimed to evaluate the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the post hoc analysis of REDUCE-IT […]

The REDUCE-IT study evaluated the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the REDUCE-IT study and n–3 fatty acid supplementation.  The abstract entitled ‘Icosapent Ethyl diminishes […]

Combining data from the DECLARE and DAPA-CKD trials enables the effect of dapagliflozin to be examined across a spectrum of baseline kidney function. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the post-hoc analysis of the DECLARE and DAPA-CKD data and the […]

Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that was studied in the DECLARE-TIMI 58 and DAPA-CKD trials. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the lessons from the DECLARE and DAPA-CKD trials about dapagliflozin’s impact on cardiovascular and renal events.  […]

Dr Yan Katsnelson, Founder, CEO, USA Vein Clinics Dr Yan Katsnelson is an entrepreneur, highly skilled cardiac surgeon, business owner, and philanthropist. He is the founder and CEO of USA Vein Clinics, which is part of USA Clinics Group – the parent company of USA Fibroid Centers, USA Vascular Centers, and USA Oncology Centers. Dr […]

The SuperWIN study is a supermarket and web-based intervention targeting nutrition. touchCARDIO spoke to Prof Dylan Steen (University of Cincinnati Medical Center, Cincinnati, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular […]